How diabetic skin needs a different kind of treatment

Living with diabetes has consequences that are often shelved as cosmetic side effects. Changes in the skin are dismissed as an inevitable consequence of aging. The drying, persistent pigmentation, gradual loss of firmness are asked to be managed with moisturizers, brightening serum or anti aging creams.

Diabetes as a condition however, attacks the skin cells. It affects their ability to repair damage and maintain structural integrity. Elevated glucose levels trigger a multitude of changes that affect the skin’s collagen, pigmentation, inflammation and the skin barrier.

Understanding glycation

Glycation is a natural, enzyme-free reaction in which excess glucose binds to proteins and lipids in the body. Over time, this process forms Advanced Glycation End Products (AGEs), compounds that accumulate throughout the body, including the skin. Collagen and elastin, the fibres responsible for skin's firmness and elasticity, are especially vulnerable. Once glycated, they stiffen and lose their natural resilience undermining the very architecture that keeps skin looking youthful.

The effects compound over time:

• Loss of elasticity as the collagen becomes rigid and less responsive
• Structural weakening as the skin's support network deteriorates
• Visible ageing with increased wrinkles and textural roughness
• Slower repair as tissue regeneration becomes less efficient
• Oxidative stress that cellular damage accelerates
• Chronic inflammation resulting in a low-grade, ongoing strain on skin health

Why diabetic pigmentation is different

Pigmentation linked to diabetes tends to resist conventional skincare because its cause isn't confined to the skin's surface. Metabolic stress and chronic inflammation overstimulate melanocytes, the cells that produce melanin. Glycation compounds this by disrupting cellular signalling, resulting in uneven melanin distribution and pigmentation that persists despite treatment. This is why darkening often concentrates in specific areas like the neck, face, underarms, knuckles and skin folds, rather than appearing as a uniform, surface-level discolouration.

Treating pigmentation at its metabolic source

As dermatological science is moving past cosmetic correction and towards the more fundamental question of what is happening inside the skin that produces pigmentation in the first place. Newer topical therapies are less concerned with masking visible pigment and more focused on the biological conditions that create it. One approach gaining particular attention involves activating AMP-activated protein kinase, or AMPK, often described as the cell's master energy regulator.

• AMP-activated protein kinase (AMPK)
  AMPK is a key cellular enzyme that regulates energy metabolism. When activated, it supports cellular repair while helping regulate inflammation and oxidative stress, two processes closely linked to diabetic skin damage. Improved AMPK activity has been associated with healthier cellular metabolism, better collagen maintenance, enhanced tissue repair, and a stronger skin barrier. This is why AMPK has become a central focus in metabolic dermatology.
  
  
• From systemic medicine to topical dermatology
  1,1-Dimethylbiguanide is well known for its metabolic effects and is now being explored in topical dermatology. Applied directly to the skin, it helps activate AMPK within skin cells, supporting healthier function where metabolic changes occur.
  
  This forms the scientific basis of Glowformin™, targeting diabetic skin at the cellular level rather than correcting surface changes alone.
  
  
• The role of bio-peptides in collagen renewal
  Diabetic skin undergoes accelerated collagen breakdown, reduced fibroblast activity, and slower extracellular matrix renewal. Bio-peptides act as signalling molecules that stimulate fibroblasts, the cells responsible for producing collagen and elastin. Over time, this supports better collagen organisation, improved elasticity, smoother texture, and firmer-looking skin. Combined with metabolic support, they help address both the biological and structural changes associated with diabetic skin ageing.

The future of diabetic dermatology

Dryness, pigmentation and premature ageing in diabetic skin are rarely separate problems. They tend to share the same origins, glycation, oxidative stress, impaired cellular metabolism and diminished collagen renewal. This is the reason behind the industry’s move towards treating each concern in isolation. 

Formulations like Glowformin™ are built around metabolic support rather than symptom masking. As the science matures, the goal is shifting from managing symptoms to giving skin back its own capacity to repair, protect and renew itself. 

References

1. Diabetes Skin Problems: Scleroderma, Vitiligo, Dermopathy  https://www.webmd.com/diabetes/skin-problems

2. Acanthosis Nigricans: Treatment, Pictures, and Causes  https://www.healthline.com/health/acanthosis-nigricans

3. Understanding and Managing Dermatologic Manifestations of Diabetes https://www.dermatologytimes.com/view/understanding-and-managing-dermatologic-manifestations-of-diabetes

4. Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs https://www.nature.com/articles/srep27848